RecruitingPhase 4ketamine

Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)

NCT ID

NCT04490031

Target Enrollment

140 participants

Start Date

2020-03-01

Est. Completion

2021-04-30

About This Study

This is a study evaluating the usage of Ketamine as sedative agent in ERCP. The usage of Ketamine will be compared to the standard sedation in our center, which is Midazolam in combination with Pethidine as analgesia.

Conditions Studied

Ketamine Adverse Reaction

Interventions

•Ketamine Hydrochloride

Eligibility

Age:16 Years - N/A

Healthy Volunteers:Yes

View full eligibility criteria

Inclusion Criteria:

* Malaysian citizens of who is able to give valid consent
* Patient planned for ERCP (either emergency or elective)

Exclusion Criteria:

* Known hypersensitivity towards Ketamine or Midazolam
* Patient refusal to participate or unable to give consent
* Increased intracranial pressure, acute stroke (\<3 months), intracranial haemorrhage (\<3 months)
* Uncontrolled hypertension (BP\>160/100) and tachycardia (Heart rate \>120)
* Acute myocardial infarction, acute coronary syndrome (\<3 months)
* Tachyarrythmia
* Pregnancy
* IVDU or substance abuse patient
* Patient with history of hallucination
* Child's Pugh Class C

Study Locations (1)

University Kebangsaan Malaysia Medical center